home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  

registry of biomedical companies

  May 24, 2024
promoting the transfer of scientific know-how between industry and academia
Registry of biomedical companies:

[3] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 461 active entries

Vybion, Inc.

584 Oak St
Monterey, CA 93940
United States of America, California

Phone: 607-227-2502
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.


Vybion is a virtual company that uses proprietary technologies develop therapeutic Intrabodies (intracellular scFvs) for unmet needs.  INT41 is a disease modifying Intrabody delivered as a Gene Therapy (rAAV) for the treatment of Huntington's disease (HD), a lethal neurodegenerative disease.  INT41 prevents oligomer and aggregate formation of mutant Huntingtin protein and gene dysregulation by targeting the toxic poyglutamine conaining N-terminal fragment of the huntingtin protein for degredation in the cytoplasm thereby reducing levels in the nucleus where gene dysregulation and perinuclear aggregates occur. Both cell-based and animal models have demonstrated efficacy and mechanism of action.  INT41 indications also include Spinocerebellar Ataxias, Spinal Muscular Atrophy and Tau pathologies. 

Selected Categories:

Product Company   Service Company
- General
- General

Last update of this entry: May 05, 2020

home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2024 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.